Search

  • HOME
  • Search
Snapshot
1861
Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
Young Chang, Soung Won Jeong, Jae Young Jang
Clin Mol Hepatol. 2024;30(1):129-133.   Published online October 13, 2023
View: 1311   Download: 94
Correspondence
Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol. 2024;30(1):126-128.   Published online November 28, 2023
View: 954   Download: 32
Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yee Hui Yeo, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):124-125.   Published online November 14, 2023
View: 920   Download: 36
Letter to the Editor
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(1):121-123.   Published online December 4, 2023
View: 1081   Download: 68  Crossref: 2
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
Clin Mol Hepatol. 2024;30(1):118-120.   Published online November 14, 2023
View: 1470   Download: 45
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji
Clin Mol Hepatol. 2024;30(1):113-117.   Published online November 10, 2023
View: 1139   Download: 62  Crossref: 1
Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Hinpetch Daungsupawong, Viroj Wiwanitkit
Clin Mol Hepatol. 2024;30(1):111-112.   Published online October 13, 2023
View: 1129   Download: 46
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”
Chi Hsiao, Yung-Po Liaw
Clin Mol Hepatol. 2024;30(1):109-110.   Published online October 11, 2023
View: 947   Download: 29
Original Article
1872
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Ying-Nan Tsai, Jia-Ling Wu, Cheng-Hao Tseng, Tzu-Haw Chen, Yi-Ling Wu, Chieh-Chang Chen, Yu-Jen Fang, Tzeng-Huey Yang, Mindie H. Nguyen, Jaw-Town Lin, Yao-Chun Hsu
Clin Mol Hepatol. 2024;30(1):98-108.   Published online December 14, 2023
View: 1425   Download: 123
1871
Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol. 2024;30(1):80-97.   Published online December 7, 2023
View: 2605   Download: 143
1868
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu
Clin Mol Hepatol. 2024;30(1):64-79.   Published online November 21, 2023
View: 1783   Download: 83
1867
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clin Mol Hepatol. 2024;30(1):49-63.   Published online November 20, 2023
View: 1869   Download: 168
1864
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity
Soomin Ahn, Sook-Hyang Jeong, Eun Ju Cho, Kyoungbun Lee, Gilhyang Kim, Haeryoung Kim
Clin Mol Hepatol. 2024;30(1):37-48.   Published online November 13, 2023
View: 1536   Download: 133
Review
1858
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, Chih-Lin Lin, Ming-Ling Chang, Chia-Chi Wang, Wei-Ting Chang, Chao-Yung Wang, Chun-Yen Lin, Chung-Lieh Hung, Cheng-Yuan Peng, Ming-Lung Yu, Ting-Hsing Chao, Jee-Fu Huang, Yi-Hsiang Huang, Chi-Yi Chen, Chern-En Chiang, Han-Chieh Lin, Yi-Heng Li, Tsung-Hsien Lin, Jia-Horng Kao, Tzung-Dau Wang, Ping-Yen Liu, Yen-Wen Wu, Chun-Jen Liu
Clin Mol Hepatol. 2024;30(1):16-36.   Published online October 4, 2023
View: 2643   Download: 236
1842
Recent advances in the management of hepatocellular carcinoma
Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang
Clin Mol Hepatol. 2024;30(1):1-15.   Published online July 21, 2023
View: 4966   Download: 258  Crossref: 2
Original Article
1752
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
George Chen, Bubu Banini, Albert Do, Joseph K. Lim
Clin Mol Hepatol. 2023;29(Suppl):S319-S332.   Published online December 14, 2022
View: 2928   Download: 97  Web of Science: 3  Crossref: 4
Review
1726
Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clin Mol Hepatol. 2023;29(Suppl):S302-S318.   Published online November 15, 2022
View: 4470   Download: 259  Web of Science: 4  Crossref: 5
1759
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra
Clin Mol Hepatol. 2023;29(Suppl):S286-S301.   Published online December 28, 2022
View: 4856   Download: 236  Web of Science: 9  Crossref: 9
1754
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management
Anja Geerts, Sander Lefere
Clin Mol Hepatol. 2023;29(Suppl):S276-S285.   Published online December 22, 2022
View: 3181   Download: 118  Web of Science: 3  Crossref: 3
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clin Mol Hepatol. 2023;29(Suppl):S261-S267.   Published online December 22, 2022
View: 2771   Download: 103  Web of Science: 4  Crossref: 4
1749
Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clin Mol Hepatol. 2023;29(Suppl):S244-S260.   Published online December 14, 2022
View: 4908   Download: 285  Web of Science: 5  Crossref: 7
1747
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clin Mol Hepatol. 2023;29(Suppl):S228-S243.   Published online December 14, 2022
View: 3150   Download: 102
1721
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(Suppl):S220-S227.   Published online November 10, 2022
View: 3135   Download: 125  Web of Science: 2  Crossref: 2
1710
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Karim Seif El Dahan, Darine Daher, Amit G. Singal
Clin Mol Hepatol. 2023;29(Suppl):S207-S219.   Published online September 14, 2022
View: 6768   Download: 157  Web of Science: 4  Crossref: 6
1741
Identification of high-risk subjects in nonalcoholic fatty liver disease
Christiane Stern, Laurent Castera
Clin Mol Hepatol. 2023;29(Suppl):S196-S206.   Published online December 5, 2022
View: 5081   Download: 270  Web of Science: 8  Crossref: 8
1738
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2023;29(Suppl):S184-S195.   Published online December 5, 2022
View: 3357   Download: 167  Web of Science: 7  Crossref: 8
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Clin Mol Hepatol. 2023;29(Suppl):S171-S183.   Published online December 12, 2022
View: 4017   Download: 248  Web of Science: 4  Crossref: 4
1728
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clin Mol Hepatol. 2023;29(Suppl):S157-S170.   Published online November 22, 2022
View: 3442   Download: 291  Web of Science: 11  Crossref: 12
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X


Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1388
TOTAL : 1737396
Close layer